Ingalls & Snyder LLC
GMAB icon

Ingalls & Snyder LLC’s Genmab GMAB Stock Holding History

Ingalls & Snyder LLC’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.66M Sell
46,417
-4,424
-9% -$140K 0.04% 180
2026
Q2 		$1.4M Sell
50,841
-22,050
-30% -$586K 0.04% 200
2026
Q1 		$1.96M Sell
72,891
-214
-0.3% -$6.41K 0.07% 156
2025
Q4 		$2.25M Sell
73,105
-34,169
-32% -$1.07M 0.08% 152
2025
Q3 		$3.29M Sell
107,274
-12,210
-10% -$298K 0.11% 122
2025
Q2 		$2.47M Sell
119,484
-29,831
-20% -$612K 0.09% 144
2025
Q1 		$2.92M Buy
149,315
+13,256
+10% +$278K 0.1% 121
2024
Q4 		$2.84M Sell
136,059
-82,424
-38% -$1.81M 0.11% 121
2024
Q3 		$5.33M Sell
218,483
-11,217
-5% -$300K 0.21% 83
2024
Q2 		$5.77M Buy
229,700
+52,117
+29% +$1.48M 0.25% 73
2024
Q1 		$5.31M Buy
+177,583
New +$5.22M 0.23% 72

Other funds holding GMAB

Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Ingalls & Snyder LLC's GMAB Position: Q3 2026 in Review

Ingalls & Snyder LLC reduced its Genmab (GMAB) stake by 8.7% in Q3 2026, selling an estimated $140K and leaving 46,417 shares worth $1.66M. The position accounts for 0.04% of the portfolio, ranked #180.

Ingalls & Snyder LLC first reported a position in GMAB in Q1 2024 and has held it in 11 quarters since. The position peaked at $5.77M in Q2 2024. 258 funds tracked by Wall St. Rank hold GMAB as of Q3 2026.

  • Ingalls & Snyder LLC held 46,417 shares of Genmab worth $1.66M as of Q3 2026.
  • Ingalls & Snyder LLC sold 4,424 Genmab shares in Q3 2026, an estimated $140K.
  • Genmab made up 0.04% of Ingalls & Snyder LLC's portfolio in Q3 2026, its #180 holding.
  • Ingalls & Snyder LLC first reported a position in Genmab in Q1 2024 and has held it in 11 quarters since.
  • Ingalls & Snyder LLC's Genmab position peaked at $5.77M in Q2 2024.
  • 258 funds tracked by Wall St. Rank held Genmab as of Q3 2026.

Based on Ingalls & Snyder LLC's 13F filing for Q3 2026, filed 12 Nov 2026.